📣 VC round data is live. Check it out!
- Public Comps
- Insulet
Insulet Valuation Multiples
Discover revenue and EBITDA valuation multiples for Insulet and similar public comparables like Cooper Companies, Medpace, Fresenius Medical Care, Globus Medical and more.
Insulet Overview
About Insulet
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetic patients are using it worldwide.
Founded
2000
HQ

Employees
5.4K
Website
Financials (LTM)
EV
$12B
Valuation Multiples
Start free trialInsulet Financials
Insulet reported last 12-month revenue of $3B and EBITDA of $693M.
In the same LTM period, Insulet generated $2B in gross profit, $693M in EBITDA, and $385M in net income.
Revenue (LTM)
Insulet P&L
In the most recent fiscal year, Insulet reported revenue of $3B and EBITDA of $640M.
Insulet is profitable as of last fiscal year, with gross margin of 72%, EBITDA margin of 24%, and net margin of 13%.
Financial data powered by Morningstar, Inc.
Insulet Stock Performance
Insulet has current market cap of $12B, and enterprise value of $12B.
Market Cap Evolution
Insulet's stock price is $175.04.
Insulet share price increased by 1.7% in the last 30 days, and decreased by 46.1% in the last year.
Insulet has an EPS (earnings per share) of $5.12.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $12B | $12B | -0.0% | 1.7% | -29.0% | -46.1% | $5.12 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialInsulet Valuation Multiples
Insulet trades at 4.2x EV/Revenue multiple, and 17.8x EV/EBITDA.
EV / Revenue (LTM)
Insulet Financial Valuation Multiples
As of May 4, 2026, Insulet has market cap of $12B and EV of $12B.
Insulet has a P/E ratio of 31.5x.
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Insulet Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Insulet Margins & Growth Rates
Insulet grew revenue by 22% and EBITDA by 25% in the last fiscal year.
In the most recent fiscal year, Insulet reported gross margin of 72%, EBITDA margin of 24%, and net margin of 13%.
Insulet Margins
Insulet Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Insulet Operational KPIs
Insulet's revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $0.3M for the same period.
Insulet's Rule of 40 is 46% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Insulet's Rule of X is 80% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
Insulet Competitors
Insulet competitors include Cooper Companies, Medpace, Fresenius Medical Care, Globus Medical, Fisher & Paykel, Solventum, Penumbra, Align Technology, Sonova and Olympus.
Most Insulet public comparables operate across Medical Devices, BioTech, DeepTech and HealthTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 3.6x | 3.5x | 11.3x | 10.9x | |||
| 4.5x | 4.4x | 20.2x | 19.8x | |||
| 1.0x | 1.0x | 5.4x | 5.4x | |||
| 4.1x | 3.9x | 14.7x | 12.4x | |||
| 16.5x | 9.1x | 32.2x | 26.7x | |||
| 1.9x | 1.9x | 6.2x | 7.1x | |||
| 8.9x | 8.5x | 55.7x | 44.2x | |||
| 2.9x | 2.9x | 10.9x | 10.6x | |||
This data is available for Pro users. Sign up to see all Insulet competitors and their valuation data. Start Free Trial | ||||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Insulet
| When was Insulet founded? | Insulet was founded in 2000. |
| Where is Insulet headquartered? | Insulet is headquartered in United States. |
| How many employees does Insulet have? | As of today, Insulet has over 5K employees. |
| Who is the CEO of Insulet? | Insulet's CEO is Ashley A. McEvoy. |
| Is Insulet publicly listed? | Yes, Insulet is a public company listed on Nasdaq. |
| What is the stock symbol of Insulet? | Insulet trades under PODD ticker. |
| When did Insulet go public? | Insulet went public in 2007. |
| Who are competitors of Insulet? | Insulet main competitors include Cooper Companies, Medpace, Fresenius Medical Care, Globus Medical, Fisher & Paykel, Solventum, Penumbra, Align Technology, Sonova, Olympus. |
| What is the current market cap of Insulet? | Insulet's current market cap is $12B. |
| What is the current revenue of Insulet? | Insulet's last 12 months revenue is $3B. |
| What is the current revenue growth of Insulet? | Insulet revenue growth (NTM/LTM) is 21%. |
| What is the current EV/Revenue multiple of Insulet? | Current revenue multiple of Insulet is 4.2x. |
| Is Insulet profitable? | Yes, Insulet is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Insulet? | Insulet's last 12 months EBITDA is $693M. |
| What is Insulet's EBITDA margin? | Insulet's last 12 months EBITDA margin is 24%. |
| What is the current EV/EBITDA multiple of Insulet? | Current EBITDA multiple of Insulet is 17.8x. |
| What is the current FCF of Insulet? | Insulet's last 12 months FCF is $393M. |
| What is Insulet's FCF margin? | Insulet's last 12 months FCF margin is 13%. |
| What is the current EV/FCF multiple of Insulet? | Current FCF multiple of Insulet is 31.5x. |
| How many companies Insulet has acquired to date? | Insulet hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies Insulet has invested to date? | Insulet hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to Insulet
Lists including Insulet
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.